Abstract Library

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3745 Prediction of disease recurrence in patients after complete PanNET G2 resection

Introduction: The number of pancreatic neuroendocrine tumors (PanNETs) detected has been increasing over the past decade. Surgical resection is the only potentially curative treatment for PanNETs, but the risk factors for recurrence are not fully understood, which is of clinical value especially for G2 PanNETs due to their high heterogeneity.

Conference:

Presenting Author:

Authors: Opalinska M, Olearska H, Sowa-Staszczak A, Morawiec-Sławek K, Kurzyńska A,

Keywords: PanNET G2, recurrence risk, NET G2, surgery, PanNET,

#3375 Neuroendocrine tumors associated with ovarian teratoma – One centre experience

Introduction: Ovarian teratomas are frequent gynaecological finding in contrary to ovarian NETs which comprise only 0.1% of all ovarian neoplasms. In contrast to other gynaecological organs like cervix, endometrium vagina or vulva in which the common type of NENs is NECs, in case of ovarian carcinoid the prognosis remains good.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Sowa-Staszczak A, Olearskaa H, Ulatowska-Bialas M, Gilis-Januszewska A,

Keywords: ovarian carcinoid, NET, teratoma, outcome,